Mississippi Center for Advanced Medicine, Madison, MS, USA.
Department of Medicine, Vanderbilt University Medical Center, Atherosclerosis Research Unit, Nashville, TN, USA.
J Clin Lipidol. 2017 Nov-Dec;11(6):1480-1484. doi: 10.1016/j.jacl.2017.08.003. Epub 2017 Aug 12.
We report a case of severe type I hyperlipoproteinemia caused by autoimmunity against lipoprotein lipase (LPL) in the context of presymptomatic Sjögren's syndrome. A 7-year-old mixed race (Caucasian/African American) girl was admitted to the intensive care unit at Vanderbilt Children's Hospital with acute pancreatitis and shock. She was previously healthy aside from asthma and history of Hashimoto's thyroiditis. Admission triglycerides (TGs) were 2191 mg/dL but returned to normal during the hospital stay and in the absence of food intake. At discharge, she was placed on a low-fat, low-sugar diet. She did not respond to fibrates, prescription fish oil, metformin, or orlistat, and during the following 2 years, she was hospitalized several times with recurrent pancreatitis. Except for a heterozygous mutation in the promoter region of LPL, predicted to have no clinical significance, she had no further mutations in genes known to affect TG metabolism and to cause inherited type I hyperlipoproteinemia, such as APOA5, APOC2, GPIHBP1, or LMF1. When her TG levels normalized after incidental use of prednisone, an autoimmune mechanism was suspected. Immunoblot analyses showed the presence of autoantibodies to LPL in the patient's plasma. Autoantibodies to LPL decreased by 37% while patient was on prednisone, and by 68% as she subsequently transitioned to hydroxychloroquine monotherapy. While on hydroxychloroquine, she underwent a supervised high-fat meal challenge and showed normal ability to metabolize TG. For the past 3 years and 6 months, she has had TG consistently <250 mg/dL, and no symptoms of, or readmissions for, pancreatitis.
我们报告了一例由脂蛋白脂肪酶 (LPL) 自身免疫引起的严重 I 型高脂蛋白血症病例,该病例发生在 Sjögren 综合征前的无症状期。一名 7 岁的混血儿(白种人和非裔美国人)女孩因急性胰腺炎和休克入住范德比尔特儿童医院重症监护病房。她除了患有哮喘和桥本甲状腺炎外,身体一直健康。入院时甘油三酯(TGs)为 2191mg/dL,但在住院期间和未进食的情况下恢复正常。出院时,她被安排低脂、低糖饮食。她对贝特类药物、处方鱼油、二甲双胍或奥利司他均无反应,在接下来的 2 年中,她因反复发作的胰腺炎多次住院。除了 LPL 启动子区域的一个杂合突变(预计无临床意义)外,她没有其他已知影响 TG 代谢并导致遗传性 I 型高脂蛋白血症的基因突变,如 APOA5、APOC2、GPIHBP1 或 LMF1。当她在偶然使用泼尼松后 TG 水平正常化时,怀疑存在自身免疫机制。免疫印迹分析显示患者血浆中存在针对 LPL 的自身抗体。患者使用泼尼松时,LPL 自身抗体减少了 37%,随后转换为羟氯喹单药治疗时减少了 68%。在使用羟氯喹期间,她接受了监督下的高脂肪餐挑战,显示出正常的 TG 代谢能力。在过去的 3 年零 6 个月里,她的 TG 一直<250mg/dL,没有胰腺炎的症状或再次住院。